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SUMMARY
The prognosis of kidney transplant recipients (KTR) with vascular calcifi-
cation (VC) in the aorto-iliac arteries is unclear. We performed a system-
atic review and meta-analysis to investigate their survival outcomes.
Studies from January 1st, 2000 until March 5th, 2019 were included. Out-
comes for meta-analysis were patient survival, (death-censored) graft sur-
vival and delayed graft function (DGF). Twenty-one studies were
identified, eight provided data for meta-analysis. KTR with VC had a sig-
nificantly increased mortality risk [1-year: risk ratio (RR) 2.19 (1.39–3.44),
5-year: RR 2.28 (1.86–2.79)]. The risk of 1-year graft loss was three times
higher in recipients with VC [RR 3.15 (1.30–7.64)]. The risk of graft loss
censored for death [1-year: RR 2.26 (0.58–2.73), 3-year: RR 2.19 (0.49–
9.82)] and the risk of DGF (RR 1.24, 95% CI 0.98–1.58) were not statisti-
cally different. The quality of the evidence was rated as very low. To con-
clude, the presence of VC was associated with an increased mortality risk
and risk of graft loss. In this small sample size, no statistical significant
association between VC and DGF or risk of death-censored graft loss could
be demonstrated. For interpretation of the outcomes, the quality and sam-
ple size of the evidence should be taken into consideration.
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Introduction
As kidney transplant recipients (KTR) are becoming
older and vascular disease is more prevalent, the chal-
lenge of transplanting a kidney onto atherosclerotic
aorto-iliac arteries is likely to become more common.
Nearly 25% of all kidney transplant candidates have
vascular calcification (VC) in the aorto-iliac arteries on
lumbar X-ray [1]. Risk factors for VC are common
risk factors for vascular disease such as diabetes,
smoking, hypertension and dyslipidemia [2,3]. Patients
suffering from end-stage renal disease (ESRD) are at
higher risk to develop vascular disease due to added
risk factors like chronic uremia, use of calcium-based
phosphate binders and, most importantly, dialysis
treatment [4]. Severe VC in the aorto-iliac arteries has
been considered as a relative contra-indication for kid-
ney transplantation (KTx). It has been found that 43%
of all transplant candidates who are considered ineligi-
ble is due to VC [5].
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There are several reasons why KTx in patients with
VC in the aorto-iliac arteries can be problematic. First,
the vascular anastomosis itself may be technically chal-
lenging. Over the years, transplant surgeons found vari-
ous ways to overcome this issue. A Fogarty catheter can
be used in case of an unclampable iliac artery [6]. In
case of compromised blood flow in the external iliac
artery (EIA) caused by VC, a percutaneous transluminal
angioplasty (PTA), endarterectomy or vascular bypass
can be performed in a staged or simultaneous proce-
dure [7]. Second, vascular complications like steal syn-
drome or trash foot may be a threat to the vascular
challenging transplant candidate [8–10]. As a third rea-
son, patients with VC are considered to have a limited
life expectancy due to cardiovascular comorbidities,
leading to a high perioperative mortality risk and limit-
ing 5-year patient survival to 35% [11,12]. Due to organ
shortage, it might not be ethical to perform a deceased
donor KTx in patients with such a limited life expec-
tancy. On the other hand, the quality of life is signifi-
cantly improved if a transplant can be performed
successfully [13]. Therefore, proper recipient evaluation
is of paramount importance.
To date, there is scant information about the progno-
sis of KTR with VC in the aorto-iliac arteries. Most
published studies are too small to provide definite con-
clusions about survival outcomes. We performed a sys-
tematic review and meta-analysis concerning clinical
outcomes after KTx in patients with VC. The primary
objective of this systematic review and meta-analysis
was to evaluate the risk of mortality and graft loss in
KTR with VC in comparison to KTR without VC. As
secondary outcomes, we investigated the risk of DGF
and 1-year kidney function.
Methods
This systematic review and meta-analysis was performed
according to the guidelines for observational studies as
described in the Preferred Reporting Items for System-
atic review and Meta-Analysis Protocols (PRISMA)
guidelines [14].
Search strategy
Together with the help from a clinical librarian, we
searched Embase, Medline, Web of Science, Cochrane and
Google Scholar database. A search for the Embase data-
base was created and the search terms for other databases
were derived from this one. The search included the
following terms: kidney/renal transplantation,
atherosclerosis, iliac artery. The first search was performed
on August 2nd 2017 and the last search on March 5th,
2019. Detailed search strategies are included in Table S1.
Study selection
The studies were firstly screened on title and abstract by
two independent reviewers (ER and JLD). Eligible study
designs were cross-sectional studies, cohort studies and
case-control studies. Studies were included if they
reported either patient survival, uncensored graft sur-
vival, death-censored graft survival, DGF or kidney
function. Studies were included in meta-analysis if they
compared clinical outcomes between KTR with any
degree of VC in the aorto-iliac arteries and KTR with-
out VC. Also, studies describing KTx outcomes after
treatment of VC [through PTA, endarterectomy (EAT)
or vascular bypass] were eligible for systematic review.
For both the meta-analysis part as well as the systematic
review part, the following exclusion criteria were used:
conference abstracts, systematic or narrative reviews,
studies published not in the English language, studies
including multi-organ transplantation and studies
published before January 1st, 2000. Disagreements were
discussed between both reviewers and, if necessary,
consulted with a third party (RCM). References were
manually checked for relevant studies.
Quality assessment
The quality of the evidence was assessed using the
GRADE tool for prognosis studies [15,16]. For the
GRADE tool, risk of bias, heterogeneity, directness of
the evidence, precision of effect estimates and risk of
publication bias were assessed for every outcome. The
Newcastle-Ottawa scale for cohort studies was adopted
to assess the quality of each individual study [17]. Stud-
ies were graded according to selection of study groups,
comparability and ascertainment of exposure and out-
comes. ER and JLD assessed the studies independently.
Data collection and extraction
Data extraction was completed by two independent
authors. The following items were extracted from
included studies that did not provide data for meta-anal-
ysis: study design, sample size per group, donor type, age,
dialysis treatment, and treatment for aorto-iliac calcifica-
tion. For studies included in meta-analysis, the following
data was extracted: study design, sample size per group,
and possible confounding factors such as recipient age,
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sex, smoking history, hypertension, diabetes mellitus,
hypercholesterolemia, hemodialysis treatment, donor
type, history with myocardial infarction or cerebrovascu-
lar accident (CVA)/transient ischemic attack (TIA). The
following outcomes were considered for meta-analysis
when compared between patients with and without VC:
patient survival, uncensored graft survival, death-cen-
sored graft survival, DGF, and kidney function. Events
for survival outcomes were deduced from Kaplan-Meier
survival curves using DataThief software and from num-
bers and percentages described in the results section [18].
Statistical analysis
For meta-analysis, pooled risk ratios (RR) with 95% con-
fidence intervals (CI) were calculated at fixed time spans
based on the number of events per group as described in
the individual studies. Because of the expected observa-
tional designs of included studies resulting in high
between-study variance, a random-effect model was used
as described by DerSimonian and Laird [19]. The Man-
tel-Haenszel analysis method was used with calculation of
the overall effect using the Z-test. To investigate potential
confounders, baseline characteristics were collected of
included patients without VC and with any VC. For con-
tinuous variables, the group mean weighed for number of
included patients was reported with pooled standard
error, if the included study reported the mean. Normality
of the means of the included studies was assumed because
of the sample size, according to the central limit theorem.
Therefore, baseline characteristics were compared with
the unpaired T-test in case of continuous variables and
with chi-square test for categorical variables using MED-
CALC software (version 16.2). Statistical heterogeneity was
visually assessed by judging overlap in the 95% confi-
dence intervals and with I2. Publication bias was assessed
using funnel plots of the logarithm of RR versus their
standard errors, which are included in the Supplemental
Digital Content [20]. A P-value below 0.05 was consid-
ered statistically significant. The program used for meta-
analysis was REVIEW MANAGER 5.3 [21].
Results
Study selection and characteristics
A total number of 1523 potentially relevant, observational
studies were identified. None of the studies describing iliac
gnineercS
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Figure 1 Preferred reporting items for systematic reviews and meta-analyses flow diagram of the systematic literature search.
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calcifications distinguished between calcifications of the
common iliac arteries or external iliac arteries. Figure 1 pre-
sents the PRISMA flow diagram. Twenty-one studies met
the inclusion criteria from which one was added after man-
ual reference check. Eight studies provided data for meta-
analysis. Characteristics of studies included in meta-analysis
are presented in Table 1 and from the studies that did not
provide data for meta-analysis in Table 2. The baseline
characteristics of the patients included in meta-analysis are
shown in Table 3. Patients with any degree of VC were
older [no vascular calcification (nVC: 42.0  12.4, any VC:
54.3  10.8, P < 0.001)], were more frequently suffering
from hypertension (nVC 75.8%, any VC 86.0%,
P < 0.001), diabetes mellitus (nVC 10.5%, any VC 32.4%,
P < 0.001) and hypercholesterolemia (nVC 27.9%, any VC
44.3%, P < 0.001). Patients with any VC had more often a
history with a myocardial infarction (nVC 6.7%, any VC
14.2%, P < 0.001) and received more frequently a living
donor kidney transplant (nVC 2.1%, any VC 5.3%,
P < 0.001). Patients with any VC were more often preemp-
tively transplanted (nVC 7.3%, any VC 16.3%, P < 0.001).
Patient survival
Seven studies provided data for meta-analysis. The for-
est plots of the comparisons made for patient survival
are shown in Fig. 2. All seven studies investigated 1-year
patient survival and showed an increased mortality risk
in patients with any VC with a pooled risk ratio (RR)
of 2.19 (n = 3381; 95% CI 1.39–3.44; P < 001) [1,22–
27]. Six studies also noted the risk of 3-year mortality
which was also increased in recipients with any VC
(n = 3272; RR: 2.17; 95% CI 1.66–2.83; P < 0.001)
[1,23–27]. Five studies mentioned 5-year mortality risk.
Similar to the pooled results of 1-year and 3-year sur-
vival, a significantly increased 5-year mortality risk was
shown in patients with any degree of VC (n = 3153;
RR: 2.28; 95% CI 1.86–2.79; P < 0.001) [1,23–25,27].
Two eligible studies were not suitable for meta-analysis.
Chavent et al. divided patients into four quartiles, based
on a CT-scan based calcification score. No difference
was found for patient survival between quartiles after a
mean follow-up of 4.18  1.64 years [28]. Rijkse et al.
[29] investigated the impact of aorto-iliac stenosis clas-
sified with the TASC II classification within a retrospec-
tive cohort study. They found a significantly decreased
patient survival in patients with TASC II C/D lesions
with a 5-year survival of 66% in the TASC II A/B
group, 26% in the TASC II C/D group and 72% in the
control group without stenosis (log-rank test TASC II
A/B: P = 0.078, TASC II C/D: P < 0.001). After
adjustment for various confounders, having a TASC II C/
D lesion was a strong, independent risk factor for mortal-
ity (HR 3.25; 95% CI 1.87–5.67; P < 0.001) [29]. Four
studies also investigated causes of death between patients
with any degree of VC and no VC. Droupy et al. found
that death from cardiovascular cause was more frequent
in patients with any VC (nVC: 2.7%, any VC: 27%,
P < 0.001) [25]. Also, Hernandez et al found that death
from a cardiovascular cause was more frequent among
recipients with any VC (nVC: 3.1%, any VC: 9.5%) [1].
Munguia et al. investigated the combined outcome of a
Major Cardiovascular Event (MACE) and cardiovascular
death. They found a statistical significant difference with
an incidence of 6.5% in KTR without VC and 21.7% in
KTR with any VC (P = 0.035) [26]. Rijkse et al. found
that, among deceased patients, death from a cardiovascu-
lar cause was more frequent in patients with any TASC II
lesion (any TASC II lesion: 35.4%, no TASC II lesion
19.1%, P = 0.035) [29].
Uncensored graft survival
Four studies, from which three provided data for meta-
analysis, reported uncensored graft survival. Figure 3
shows the pooled results of those studies. The risk of
one-year graft loss was three times higher in KTR with
any VC (n = 321; RR: 3.15; 95% CI 1.30–7.64;
P = 0.01) [22,26,30]. The risk of 3-year graft loss was
investigated in two studies. The pooled RR showed no
significant higher risk of graft failure in KTR with VC
(n = 212; RR: 3.41; 95% CI 0.97–11.96; P = 0.05)
[26,30]. Rijkse et al. [29] also found a significant graft
survival difference between KTR with a TASC II C/D
lesion in comparison to KTR without any TASC II
lesions (5-year graft survival: no TASC II lesions: 60%,
TASC II C/D lesion: 22%, log-rank test: P < 0.001).
Death-censored graft survival
Five studies reported death-censored graft survival in
recipients with any VC without an additional vascular
procedure. Only two provided data for meta-analysis.
Figure 4 shows the forest plots with pooled RR. The
risk of death-censored graft loss was not significantly
different between KTR with and without VC with a RR
of 2.26 (n = 1189; 95% CI 0.58–8.82; P = 0.24) [25,26].
Also, the risk of 3-year death-censored graft loss was
statistically similar (n = 1189; RR: 2.19; 95% CI 0.49–
9.82; P = 0.31) [25,26]. Three eligible studies were not
suitable for meta-analysis. Chavent et al. reports no dif-
ference in overall death-censored graft survival after a
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mean follow-up of 4.18  1.64 years (P = 0.7) [28].
Hwang et al. [31] found a significant difference in over-
all death-censored graft survival between patients with
positive intimal calcification in comparison with
patients with negative intimal micro-calcification (log-
rank test P = 0.017). Rijkse et al. [29] found no signifi-
cant association between the presence of aorto-iliac
stenosis as classified with the TASC II classification and
death-censored graft loss [TASC II A/B: HR 0.78 (0.41–
1.50), TASC II C/D: HR 1.85 (0.74–4.65)].
Delayed graft function
Out of five studies reporting the incidence of DGF, four
provided data for meta-analysis. The pooled RR, as
shown in the forest plot depicted in Fig. 5, showed no sta-
tistical significant difference for risk of DGF (n = 1391;
RR: 1.24; 95% CI 0.98–1.58; P = 0.08) [22,25,26,30].
Hwang et al. [31] found no significant difference in the
incidence of DGF between patients with and without inti-
mal microcalcification (22.9% vs. 21.4%, P = 0.204).
Kidney function
Five studies investigated the impact of VC on 1-year creati-
nine. Due to the large heterogeneity between studies (I2 of
81%), it was decided not to pool the results. Aalten et al.
[22] found a mean serum creatinine of 130  38 µmol/l in
KTR with VC and 131  41 µmol/l in KTR without VC,
which was not statistically different. The study of Aitken
et al. also found no statistical significant difference (VC:
148.5  9.6, nVC: 140.3  8.9) [30]. Munguia et al. inves-
tigated serum creatinine after 1 month (nVC:
1.90  0.13 mg/dl, VC: 1.79  0.10 mg/dl), 3 months
(nVC: 1.63  0.06 mg/dl, VC: 1.69  0.10 mg/dl), and
1 year (nVC: 1.57  0.07 mg/dl, VC: 1.55  0.11 mg/dl).
No significant difference was found [26]. Hernandez et al.
investigated the percentage of patients with a serum crea-
tinine >2 mg/dl at discharge. He found that the proportions
were not significantly different (VC 23.4%, nVC 27.3%, P-
value 0.248) [1]. Chavent et al. found that creatinine levels
were significantly higher at last-follow-up (mean
4.18  1.64) in the fourth quartile with the most severe cal-
cification (P = 0.046), but this result was not significant
when the glomerular filtration rate was calculated with the
MDRD formula (P = 0.1) [28].
KTx on a prosthetic graft
Nine studies were published in which kidney trans-
plants were connected to a prosthetic graft. In threeT
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studies, numbers were too small for further analysis
[32–34]. One study did not describe the results of
those patients separately [29]. Table 4 presents the eli-
gible studies. A total number of 57 cases were
described in which the kidney transplant was con-
nected to a prosthetic graft [35–39]. The incidence of
DGF was described in 53 patients from which 4
(7.5%) had a DGF [35–37,39]. The incidence of
Table 3. Baseline characteristics of patients included in meta-analysis.
Characteristics Studies nVC Total patients Any VC Total patients P-value
Recipient age, mean (SD) 61,22,23,25,26,27 42.0 (12.4) 2529 54.3 (10.8) 721 <0.001*
Male sex, n (%) 51,22,23,26,27 977 (63.9) 1528 421 (64.6) 652 0.779
Smoking, n (%) 222,23 99 (19.5) 508 59 (19.5) 302 <0.986
Hypertension, n (%) 41,22,23,27 1106 (75.8) 1459 518 (86.0) 602 <0.001*
DM, n (%) 51,22,23,26,27 160 (10.5) 1528 211 (32.4) 652 <0.001*
Hypercholesterolemia, n (%) 31,23,27 387 (27.9) 1385 251 (44.3) 567 <0.001*
Pre-emptive KTx, n (%) 51,22,23,25,26 176 (7.3) 2422 113 (16.3) 694 <0.001*
Living donor, n (%) 31,22,25 41 (2.1) 1919 20 (5.3) 377 <0.001*
History MI, n (%) 222,23 34 (6.7) 508 43 (14.2) 302 <0.001*
History CVA/TIA, n (%) 222,23 28 (5.5) 508 27 (8.9) 302 0.061
CVA, cerebrovascular accident; DM, diabetes mellitus; KTx, kidney transplantation; MI, myocardial infarction; nVC, no vascular calci-
fication; SD, standard deviation; TIA, transient ischemic attack; VC, vascular calcification. * indicates statistical significance.
Figure 2 Risk of 1-, 3- and 5-year mortality in recipients with any degree of vascular calcification (VC) and without VC.
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postoperative complications was 19.3% and complica-
tions described were renal vein thrombosis (n = 1),
bleeding (n = 5), rejection (n = 1), lower limb
amputation (n = 1), thrombosis below the graft
(n = 1), infection (n = 2), and surgical wound dehis-
cence (n = 1) [35–39]. A re-operation was needed in
Figure 3 Risk of 1- and 3-year graft loss uncensored for death in recipients with any degree of vascular calcification (VC) and without VC.
Figure 4 Risk of 1- and 3-year death-censored graft loss in recipients with any degree of vascular calcification (VC) and without VC.
Figure 5 Risk of delayed graft function in recipients with any degree of vascular calcification (VC) and without VC.
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7.0% of the recipients [35–39]. Thirty-day patient,
death-censored and uncensored graft survival was
100%, 90.0% and 90% respectively [35,36,38,39]. One-
year patient survival, uncensored and death-censored
graft survival was 93.5%, 93.5% and 89.1% respectively
[35,37–39]. Five-year survival outcomes were only
mentioned in one study. In this study, 5-year patient
survival, death-censored and uncensored graft survival
was 85.2%, 90.3% and 74.1% respectively [37]. Cole-
man et al. described the usage of a vascular conduit in
10 patients (n = 8 donor iliac artery graft, n = 2
saphenous vein graft) to facilitate KTx in case of lim-
ited anastomotic options due to iliac calcification [40].
No postoperative mortality or graft loss was observed.
Two patients had a fascial dehiscence as a complica-
tion, and two patients had DGF [40].
KTx after endarterectomy
Six studies discussed clinical outcomes after KTx in
patients who underwent simultaneous iliac artery
endarterectomy. All of them mentioned 1-year patient
survival, as shown in Table 5. One-year patient survival
varied from 86.6% till 100% in patients who underwent
endarterectomy (EAT) [25,32–34,39,41]. Three studies
used a control group of patients without VC and they
all showed no statistical significant difference for 1-year
patient survival [25,32,41]. Three studies also investi-
gated 5-year patient survival, from which one showed a
significant difference in favor of patients without VC
(nVC 87  1, VC + EAT 69  8, P < 0.001) [25]. Five
studies noted 1-year uncensored graft survival, which
varied from 80% to 100% [32–34,39,41]. Two studies
compared the results with KTR without VC, which was
not statistically different [32,41]. One-year death-cen-
sored graft survival was investigated in three studies
and varied from 87–100%, from which two studies
used a control group of recipients without VC
[33,34,39]. Droupy et al. found no significant difference
for 1-year death-censored survival, but 5-year death-
censored graft survival was inferior in recipients who
underwent EAT (70  2, 46  7, P < 0.001) [25]. In
the study from Han et al., 1- and 5-year death-censored
graft survival was equal between both groups [32]. The
incidence of DGF was investigated in two studies.
Droupy et al. found no difference in the incidence of
DGF between KTR without VC and KTR with
VC + EAT (37%, 42%, NS) [25]. Han et al. [32] con-
firms these results with an incidence of 2.0% in the
KTR without VC group and 7.4% in the KTR with
VC + EAT group (P = 0.099).Ta
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Quality of evidence, publication bias and statistical
heterogeneity
Because all included studies were observational, the
baseline quality of the evidence was graded as low. The
GRADE assessment can be found in Table S2. The final
quality assessment for every outcome was downgraded
to “very low” because of the accompanying high risk of
bias associated with the usage of unadjusted RR.
Because of the high risk of bias, the quality of the evi-
dence was not upgraded if the association was strong
(RR >2). For the mortality outcome, between study
heterogeneity was low with an I2 of 0% for both 1-year,
3-year and 5-year mortality. For 1-year graft loss
uncensored for death, between study heterogeneity was
also low (I2 0%). For 3-year graft loss uncensored for
death, we found substantial heterogeneity with an I2 of
57%. For the risk of 1-year and 3-year death-censored
graft loss, heterogeneity was either low (1-year: I2 28%)
or moderate (I2 57%). For the outcome DGF, hetero-
geneity was also low (I2 0%). According to the New-
castle-Ottawa scale, the quality of three studies was
considered good, and for five studies poor. Reasons to
consider a study of poor quality were often a combina-
tion of no adjustment for confounding, a short follow-
up time or no description of the percentage lost to fol-
low-up. Funnel plots to assess publication bias are
added in the Figs S1–S4. No important publication bias
could be found for the studies that provided data for
meta-analysis.
Discussion
Our meta-analysis demonstrated that the presence of
any VC is associated with an increased mortality risk
and risk of 1-year graft loss. This is in line with our
expectations, because there is a strong association
between large-vessel peripheral arterial disease and car-
diovascular mortality [42]. Indeed, the incidence of car-
diovascular death was more frequent in deceased KTR
with any degree of VC. As expected, risk factors for vas-
cular disease were more prevalent in patients with any
degree of VC. Our meta-analysis did not demonstrate a
statistical significant difference for risk of death-cen-
sored graft loss or DGF. However, the pooled RR’s for
these outcomes and the wide confidence intervals sug-
gest that this may be attributable to the small sample
size. Studies describing results from KTx on a prosthetic
graft or after endarterectomy were scarce and results
varied largely. Patients who died after bypass surgery
and did therefore not receive a kidney transplant areT
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not taken into account, creating guarantee-time bias. As
a result, survival outcomes of kidney transplantation on
a prosthetic graft might be too optimistic.
Our meta-analysis has some important limitations.
First, all studies were observational, which means that
there is much confounding we could not correct for.
We compared baseline characteristics to give an indi-
cation of the existing confounders. Confounders
known to increase the mortality risk were more
prevalent in KTR with any degree of VC. Factors
associated with better graft survival, such as a living
donor transplant and preemptive transplantation, were
also more frequent in KTR with any degree of VC.
This may be due to possible selection bias of the
transplant surgeon to improve outcomes and to guar-
antee daytime surgery. Another limitation is instru-
ment variability because of the different methods used
to diagnose VC. In two studies, VC was diagnosed
during surgery, which may lead to underdetection.
Other studies used an X-ray or CT-scan to diagnose
VC. According to Aitken et al. [30], sensitivity and
specificity for pelvic X-ray to diagnose VC in compar-
ison to CTA were 98.5% and 92.6% respectively. Both
pelvic X-ray (sensitivity 95.5%, specificity 83.1%) and
CTA (sensitivity 100%, specificity 92%) correlated well
with intraoperative assessment of the vessels [30].
Therefore, we think that the usage of different imag-
ing modalities did not largely affect our results.
Because of the different scoring systems used and the
different methods to diagnose VC, we could not
investigate a dose-response relationship. Therefore, we
decided to use the dichotomous outcome of no VC/
any degree of VC to decrease misclassification. The
studies in our meta-analysis did not all describe if
patients with any VC who received pre-transplant
PTA were excluded. If patients after PTA were
included in the study, graft survival estimates could
have been diluted towards the null when compared to
untreated VC. Also, no distinction could be made
between VC and hemodynamically significant stenosis.
It may be possible that VC only impacts death-cen-
sored graft survival outcomes in case of a hemody-
namically significant stenosis. Rijkse et al. investigated
this and did not find a statistical significant difference
[TASC II A/B: HR 0.78 (0.41–1.50), TASC II C/D:
HR 1.85 (0.74–4.65)] [29]. However, in this study,
the sample size of KTR with significant stenosis was
small. Larger studies are needed to provide definite
answers to this question.
This meta-analysis is the first one to describe the
overall prognosis of KTR with any degree of VC.
Besides the observational study designs, low between
study heterogeneity was observed. We were able to
show important factors associated with the less opti-
mistic prognosis of KTR with any degree of VC. For
this meta-analysis, we were only able to look at the
dichotomous outcome of any VC/ no VC. Future
studies should focus on finding a dose-response effect
of the amount of VC. Also, a standardized classifica-
tion should be used to reduce heterogeneity between
studies and to allow risk stratification. Even though
the study designs were not optimal for meta-analysis,
we carefully selected studies to include in our meta-
analysis and therefore, we believe this is the best avail-
able evidence on this subject. Because of all confound-
ing factors, we could not investigate whether VC is an
independent risk factor for mortality and graft loss.
The value of VC as an independent risk factor should
be investigated for usage in post-transplant risk adjust-
ment models, such as the Scientific Registry of Trans-
plant Recipients (SRTR) post-transplant risk
adjustment models [43].
Conclusion
The presence of VC in KTR is associated with an
increased mortality risk and increased risk of graft
loss. No statistical significant association between VC
and DGF or risk of death-censored graft loss could
be demonstrated. However, for the interpretation of
the outcomes, the quality, risk of bias and sample
size of the available evidence should be taken into
consideration.
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